These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25076326)

  • 1. KRAS in pancreatic cancer.
    Agarwal A; Saif MW
    JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
    Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
    Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological identification of ampullary adenocarcinomas.
    Relias V; Saif MW
    JOP; 2014 Jul; 15(4):306-7. PubMed ID: 25076327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Kras oncogene and pancreatic cancer: thirty years after].
    Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
    Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled with a KRAS mutation assay using allelic discrimination improves the diagnosis of pancreatic cancer.
    Bournet B; Selves J; Grand D; Danjoux M; Hanoun N; Cordelier P; Buscail L
    J Clin Gastroenterol; 2015 Jan; 49(1):50-6. PubMed ID: 24798941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas.
    Krasinskas AM; Chiosea SI; Pal T; Dacic S
    Mod Pathol; 2014 Feb; 27(2):262-70. PubMed ID: 23887294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
    Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
    Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KRAS-PDEδ interaction is a therapeutic target.
    Cancer Discov; 2013 Jul; 3(7):OF20. PubMed ID: 23847364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.
    Mohelnikova-Duchonova B; Brynychova V; Hlavac V; Kocik M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Melichar B; Soucek P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):669-82. PubMed ID: 23934321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
    Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
    Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
    Schultz NA; Roslind A; Christensen IJ; Horn T; Høgdall E; Pedersen LN; Kruhøffer M; Burcharth F; Wøjdemann M; Johansen JS
    Pancreas; 2012 Jul; 41(5):759-66. PubMed ID: 22699145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.
    Duan YF; Li DF; Liu YH; Mei P; Qin YX; Li LF; Lin QX; Li ZJ
    Hepatobiliary Pancreat Dis Int; 2013 Apr; 12(2):204-9. PubMed ID: 23558076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kras mutation analysis of fine needle aspirate under EUS guidance facilitates risk stratification of patients with pancreatic mass.
    Maluf-Filho F; Kumar A; Gerhardt R; Kubrusly M; Sakai P; Hondo F; Matuguma SE; Artifon E; Monteiro da Cunha JE; César Machado MC; Ishioka S; Forero E
    J Clin Gastroenterol; 2007; 41(10):906-10. PubMed ID: 18090159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in ampullary cancer: potential role of different KRAS mutations.
    Valsangkar NP; Ingkakul T; Correa-Gallego C; Mino-Kenudson M; Masia R; Lillemoe KD; Fernández-del Castillo C; Warshaw AL; Liss AS; Thayer SP
    Surgery; 2015 Feb; 157(2):260-8. PubMed ID: 25616942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles for KRAS in pancreatic tumor development and progression.
    di Magliano MP; Logsdon CD
    Gastroenterology; 2013 Jun; 144(6):1220-9. PubMed ID: 23622131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.